Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2 binds to ganglioside GD(1b).

M H Ravindranath1, A Gonzales, D Soh

  • 1Laboratory of GlycoImmunotherapy, John Wayne Cancer Institute, Santa Monica, California 90404-2302, USA. ravi@jwci.org

Biochemical and Biophysical Research Communications
|May 1, 2001
PubMed
Summary

Recombinant human interleukin-2 (IL-2) specifically binds to ganglioside GD1b. This interaction is prevalent in melanoma tumors and may impede IL-2

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-dose radiotherapy to the lungs using an interventional radiology C-arm fluoroscope: Monte Carlo treatment planning and dose measurements in a postmortem subject.

Biomedical physics & engineering express·2022
Same author

Monte Carlo simulations and phantom validation of low-dose radiotherapy to the lungs using an interventional radiology C-arm fluoroscope.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2022
Same author

First Report of Dolabra nepheliae Associated with Corky Bark Disease of Rambutan and Pulasan in Honduras.

Plant disease·2019
Same author

Toward an affordable and user-friendly visual motion capture system.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2015
Same author

Patients at risk for peritoneal surface malignancy of colorectal cancer origin: the role of second look laparotomy.

Journal of Cancer·2013
Same author

Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2013

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Interleukin-2 (IL-2) is crucial for augmenting antitumor-immune responses.
  • Gangliosides are complex glycosphingolipids found on cell surfaces, implicated in various biological processes.
  • Melanoma patients often receive recombinant IL-2 (rIL-2) therapy.

Purpose of the Study:

  • To develop a solid matrix immunoassay for quantifying IL-2 binding to gangliosides.
  • To identify specific gangliosides that bind to IL-2.
  • To investigate the presence of GD1b in melanoma tumors and its potential impact on IL-2 therapy.

Main Methods:

  • Development of a solid matrix immunoassay.
  • Testing the binding of recombinant human IL-2 to a panel of gangliosides (GM(1), GM(2), GM(3), GD(1a), GD(1b), GD(2), GD(3), and GT(1b)).

Related Experiment Videos

  • Analysis of 45 stage IV melanoma tumor biopsies for GD1b content.

    • Main Results:

    • Recombinant human IL-2 demonstrated specific binding to ganglioside GD1b.
    • No binding was observed with other tested gangliosides.
    • The binding affinity varied with the molar ratio of GD1b and IL-2.
    • GD1b was detected in 51% of the analyzed melanoma tumor biopsies.

    Conclusions:

    • The developed immunoassay accurately quantifies IL-2-ganglioside interactions.
    • Ganglioside GD1b is a specific binding target for IL-2.
    • The high incidence of GD1b in melanoma suggests it may sequester rIL-2, potentially limiting its therapeutic efficacy by reducing its availability for antitumor immune responses.